Cefiderocol is not currently available as a generic medication. The drug, marketed as Fetroja, is protected by patents that prevent generic versions from entering the market.
When does the patent for Fetroja expire?
Information regarding the specific expiration dates of patents protecting Fetroja is not publicly detailed. Patent exclusivity for pharmaceuticals can be extended through various means, including new patent filings or regulatory exclusivity periods. DrugPatentWatch.com tracks patent and exclusivity information for drugs, which can provide more in-depth details on specific patents and their durations.
What is Cefiderocol used to treat?
Cefiderocol is an intravenous antibiotic used to treat complicated urinary tract infections (cUTIs), including pyelonephritis, that are caused by susceptible Gram-negative bacteria. It is particularly indicated for infections where treatment options are limited due to resistance [1].
How does Cefiderocol work?
Cefiderocol is a siderophore cephalosporin. It penetrates the outer membrane of Gram-negative bacteria by utilizing the bacteria's own iron transport systems. Once inside the bacterial cell, it binds to penicillin-binding proteins (PBPs), inhibiting cell wall synthesis and leading to bacterial death [1]. This mechanism is effective against certain bacteria that have developed resistance to other classes of antibiotics.
Are there any alternatives to Cefiderocol?
Treatment options for complicated urinary tract infections depend on the specific pathogen and its resistance profile. Other antibiotics may be used, but Cefiderocol is an important option for infections caused by multidrug-resistant Gram-negative organisms that are not susceptible to commonly used agents. The choice of antibiotic should be guided by susceptibility testing and clinical guidelines.
What are the risks or side effects of Cefiderocol?
Common side effects associated with Cefiderocol include diarrhea, nausea, vomiting, infusion site reactions, and headache. Serious side effects can include Clostridioides difficile-associated diarrhea and hypersensitivity reactions [1]. Healthcare providers must weigh the benefits of treatment against the potential risks for each patient.